Mehdi Hamadani Selected Research

Therapeutics

5/2024	Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis.
4/2024	ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy.
2/2024	Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma.
1/2024	SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
12/2023	Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis.
12/2023	Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy.
12/2023	Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.
12/2023	Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
10/2023	Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma.
8/2023	Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mehdi Hamadani Research Topics

Disease

44	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 02/2024 - 10/2008
40	Lymphoma (Lymphomas) 01/2024 - 12/2007
38	Graft vs Host Disease (Graft-Versus-Host Disease) 06/2023 - 12/2006
35	Multiple Myeloma 04/2024 - 03/2008
31	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2024 - 03/2009
28	Neoplasms (Cancer) 01/2024 - 06/2007
19	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2023 - 03/2009
18	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2023 - 10/2008
16	Hematologic Neoplasms (Hematological Malignancy) 12/2023 - 07/2008
16	Hodgkin Disease (Hodgkin's Disease) 12/2021 - 10/2015
15	B-Cell Lymphoma (Lymphoma, B Cell) 05/2024 - 11/2008
13	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 03/2024 - 05/2008
8	Leukemia 01/2024 - 04/2008
7	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2023 - 04/2017
7	Infections 12/2020 - 11/2009
6	Thrombocytopenia (Thrombopenia) 02/2024 - 01/2019
6	T-Cell Lymphoma (Lymphoma, T Cell) 06/2022 - 04/2008
6	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 06/2022 - 04/2008
6	Amyloidosis 12/2019 - 12/2014
5	Bronchiolitis Obliterans Syndrome 01/2024 - 01/2020
5	Neutropenia 12/2023 - 01/2019
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2020 - 01/2016
4	Pathologic Complete Response 05/2024 - 02/2014
4	Cytopenia 04/2024 - 09/2013
4	COVID-19 01/2024 - 01/2020
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2022 - 03/2016
4	Nausea 01/2021 - 06/2006
3	Exanthema (Rash) 12/2023 - 12/2006
3	Disease Progression 10/2023 - 01/2016
3	Cytokine Release Syndrome 11/2021 - 01/2018
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2021 - 01/2017
3	Fatigue 01/2021 - 11/2017
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2020 - 03/2015
3	Immunoglobulin Light-chain Amyloidosis 12/2019 - 12/2014
3	Mucositis 01/2019 - 01/2017
2	Anemia 02/2024 - 10/2019
2	Residual Neoplasm 12/2023 - 01/2016
2	Waldenstrom Macroglobulinemia (Macroglobulinemia) 02/2022 - 01/2017
2	cell-associated neurotoxicity 01/2022 - 12/2021
2	Diarrhea 10/2021 - 12/2006
2	Fever (Fevers) 10/2021 - 01/2019
2	Edema (Dropsy) 01/2021 - 11/2017
2	Splenomegaly 01/2020 - 09/2012
2	Primary Myelofibrosis (Myelosclerosis) 01/2020 - 01/2014
2	Thrombotic Microangiopathies 01/2020 - 11/2017

Drug/Important Bio-Agent (IBA)

24	Chimeric Antigen ReceptorsIBA 05/2024 - 12/2019
19	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2024 - 07/2012
14	Rituximab (Mabthera)FDA Link 10/2023 - 12/2007
10	loncastuximab tesirineIBA 02/2024 - 12/2019
10	Calcineurin InhibitorsIBA 01/2024 - 02/2016
7	ixazomibIBA 01/2024 - 12/2014
7	Monoclonal AntibodiesIBA 10/2023 - 07/2008
7	plerixafor FDA Link 12/2019 - 01/2012
6	SteroidsIBA 11/2021 - 12/2006
6	Melphalan (Alkeran)FDA LinkGeneric 12/2020 - 01/2018
6	Busulfan (Busulfex)FDA Link 01/2020 - 12/2013
6	Antilymphocyte Serum (Anti-Thymocyte Globulin)IBA 01/2020 - 11/2009
6	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2019 - 01/2012
6	Lenalidomide (CC 5013)FDA Link 01/2019 - 12/2014
6	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 06/2007
5	fludarabineIBA 10/2020 - 01/2018
5	ibrutinibIBA 01/2020 - 10/2015
5	Proteasome InhibitorsIBA 01/2020 - 12/2014
5	Bortezomib (Velcade)FDA Link 01/2019 - 12/2014
4	Methotrexate (Mexate)FDA LinkGeneric 01/2024 - 01/2018
4	Biomarkers (Surrogate Marker)IBA 10/2023 - 11/2015
4	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 12/2019
4	ruxolitinibIBA 11/2021 - 01/2019
4	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2020 - 12/2006
3	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 11/2023 - 07/2021
3	axicabtagene ciloleucelIBA 01/2022 - 12/2019
3	Propranolol (Inderal)FDA LinkGeneric 01/2022 - 05/2018
3	Anaplastic Lymphoma KinaseIBA 01/2021 - 01/2017
2	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 02/2024 - 12/2023
2	Immunoglobulin G (IgG)IBA 01/2024 - 05/2023
2	Bendamustine Hydrochloride FDA Link 12/2023 - 01/2019
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2023 - 06/2022
2	Tacrolimus (Prograf)FDA LinkGeneric 06/2023 - 01/2018
2	Mycophenolic Acid (Cellcept)FDA LinkGeneric 06/2023 - 10/2019
2	pembrolizumabIBA 01/2023 - 01/2019
2	tocilizumab (atlizumab)FDA Link 01/2023 - 01/2018
2	Prednisone (Sone)FDA LinkGeneric 01/2023 - 12/2006
2	Tyrosine Kinase InhibitorsIBA 12/2022 - 01/2020
2	EnzymesIBA 01/2022 - 01/2021
2	tisagenlecleucelIBA 01/2022 - 12/2019
2	Brentuximab VedotinIBA 12/2021 - 01/2021
2	Immunomodulating AgentsIBA 01/2020 - 10/2017
2	Alemtuzumab (Campath)FDA Link 01/2020 - 09/2013

Therapy/Procedure

123	Cell Transplantation 03/2024 - 01/2011
89	Therapeutics 05/2024 - 12/2006
48	Transplantation 01/2024 - 07/2008
28	Homologous Transplantation 01/2024 - 04/2008
20	Drug Therapy (Chemotherapy) 01/2024 - 06/2006
15	Hematopoietic Stem Cell Transplantation 08/2023 - 04/2008
14	Autologous Transplantation 02/2022 - 09/2013
9	Stem Cell Transplantation 01/2022 - 07/2008
7	Salvage Therapy 01/2023 - 01/2016
6	Immunotherapy 01/2022 - 11/2014
3	Haploidentical Transplantation 10/2019 - 01/2018
2	Radiotherapy 02/2023 - 12/2021